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Involvement of carotenoids in the synthesis and in the assembly of protein 
subunits of photosynthetic reaction centers of Synechocystis sp. PCC 6803 
Ozge Sozer 
Ins t i tu te of Plant Biology, Biological Research Center , H u n g a r i a n A c a d e m y of Sciences, Szeged , H u n g a r y 
The crtB gene of Synechocystis sp. PCC 6803. encoding phytoene synthase, was inactivated in the AcriH mutant. Thus, a carotenoid-less 
mutant, AcrtH/B, was produced. Cells of the mutant were light sensitive and could grow only under light-activated heterotrophic growth 
conditions in the presence of glucose. Carotenoid deficiency did not significantly affect the cellular content of phycobiliproteins while the 
chlorophyll content of the mutant cells decreased. The mutant cells exhibited no oxygen-evolving activity suggesting the absence of photo-
chemically active PSIl complexes. This was confirmed by 2D electrophoresis of photosynthetic membrane complexes. Analyses identified 
only a small amount of a non-functional PSII core complex lacking CP43. while the monomelic and dimeric PSIl core complexes were 
absent. On the other hand, carotenoid deficiency did not prevent formation of Cyt ¿ / complex and PSI, which predominantly accumulated 
in the monomelic form. Radioactive labeling revealed very limited synthesis of inner PSII antennae. CP47. and especially CP43. Thus, 
carotenoids are indispensable constituents of the photosynthetic apparatus being essential not only for the anti-oxidative protection, but 
also for the efficient synthesis and accumulation of photosynthetic proteins and especially that of PSIl antenna subunits. 
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Galectin-I (Gal-1) has a powerful anti-inflammatory effect (Kiss et al. 2007: Veronika et al. 2008) dominantly due to the induction of 
apoptosis of activated T cells (Ion et al. 2005. 2006). Gal-1 expression or overexpression in a tumor or in the tumor associated stroma must 
be considered as a sign of a poor prognosis for patients (Camby et al. 2006). Recent literature data report about the role of bone marrow 
derived mesenchymal stem cells (bmMSCs) in the process of tumorigenesis. It has been shown in these studies that bmMSCs selectively 
migrate into the tumor sites and are engrafted in the tumor stroma (Berber et al. 2009). Moreover bmMSCs may contribute to the formation 
of tumor associated stroma supporting the progression of cancerous cells, may regulate the neoangiogenesis and prevent the tumor specific 
immune response (Lazennec 2008). Several proteomic studies revealed the Gal-1 expression in mesenchymal stem cells (Silva et al. 2003; 
Panepucci et al. 2004: Kadri 2005: Lepelletier et al. 2009) however its role in MSC has to be elucidated. 
Our purpose was to examine the role and influence of bmMSCs and brnMSC derived Gal-1 in the course of primary tumor develop-
ment and metastasis. 
We examined the Gal-1 production in MSCs in Western blot and FACS experiments. Balb/C or C57B1/6 mice were subcutaneously 
injected with 4TI breast carcinoma or B16F10 melanoma cells, respectively with or without bmMSCs. Primary tumor size was regularly 
measured. After sacrificing the animals, weight of the lung and number of metastatic nodules were analyzed. Histochemical analysis was 
also carried out on different tissues isolated from treated mice. We established Gal-1 knock-down MSCs in order to investigate their effect 
in tumor progression, neovascularization and metastasis. 
Co-injection of bmMSCs with 4T1 breast carcinoma or B16F10 melanoma tumor cells induced larger primary tumor size and increased 
necrotic lesions on the 3rd week after treatment compared to these parameters in animals treated with the tumor cells alone. Metastatic 
phenotype characterized by the lung mass and the number of metastatic nodules is also more pronounced in animals injected with combina-
tion of tumor cells and bmMSCs. Histopathology also confirms the participation of bmMSCs in the pathogenesis of cancer, since bmMSCs 
enhance the number of micrometastasis in lungs and in lymph nodes. Moreover we detected CM-Dil labeled MSCs in the tumor samples 
on the 3rd week after treatment. Co-transplantation of Gal-1 knock-down MSCs with 4T1 cells slowed down the 4T1 tumor growth and 
vascularization compared to that of the effect of wild type MSCs. 
In this study we show that bmMSCs enhance the growth kinetics of the primary orthotropic 4TI mouse breast carcinoma and BI6F10 
melanoma. Also they contribute to progression of metastatic phenotype of the investigated tumor models. Supportive effect of bmMSCs 
to the tumor progression prevails on the 3rd week of treatment, since co-injection of bmMSCs with tumor cells do not modify the survival 
period of the animals. MSC derived Gal-1 could play an important role in the tumor promoting effect of MSCs. 
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Studying the chromatin structure of MDR1 gene in drug-sensitive and drug-
resistant human cells 
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The reason for failure of chemotherapy is often the developmenl of multidrug resistance, which is caused by the elevated level of ABC (ATP 
binding cassette) type transporters. One of the most often described ABC transporter is encoded by the MDRl (multidrug resistance l) 
gene. It was earlier described that drug induced upregulation of MDRl is associated with increased H3 acetylation level in discrete region 
of MDRl locus. Therefore exploration of the epigenetic mechanisms that contribute to the development of multidrug resistance has great 
importance. Several human diseases may originate from impaired function of histone acetyl transferases (HATs): therefore, these enzymes 
will serve as novel molecular targets for therapy in the future. 
We aimed to study the changes in specific histone acetylation upon MDRl gene induction and to analyze the histone acetyl transferase 
complexes that are responsible for these modifications. 
We characterized a drug resistant. MCF7-derived, breast carcinoma cell line named MCF-KCR. Il was generated via long temi treat-
ment of MCF7 cells with doxorubicin. We examined the level of MDRI gene and mRNA in these cell lines. We found that the MDRI gene 
level is 17 fold while the mRNA level 23000 fold elevated in the drug-resistant cells compared to the parental cells. These data suggest that 
epigenetic upregulation of MDRl transcription is more important in developing the drug resistance than gene amplification. Importantly, 
the level of MRP1 (multidrug resistance protein 1) mRNA was not elevated in the drug resistant cells. 
We showed by immunoblotting that the global H3 acetylation is elevated in the MCF-KCR cells. In addition, we examined the histone 
acetylation pattern in the regulatory regions (two promoters) and the coding region of the MDRl gene by employing chromatin immu-
noprecipitation. Our data reveal an interesting acetylation map. With the use of acetylated residue specific antibodies we found that the 
acetylation level of H3K9 is about 100 fold elevated in the downstream promoter region and in the first exon in the drug resistant subline 
compared to the drug sensitive cells. H3K4. H3K14 and H4K12 are also slightly increased in the downstream promoter region and in the 
first exon of the MDRl gene in those cells that overexpress MDRl mRNA (Toth et al. 2009). 
When we treated the cells with trichostatin A (TSA). a histone deacetylase inhibitor, MDRl expression increased, while that of the 
other genes examined did not change in the drug sensitive cells. In contrast. MDR I mRNA level did not change in the drug resistant cells 
upon TSA treatment. To try to down-regulate the acetylation and. along with that, the expression of the MDR 1 gene, we treated the cells 
with a novel HAT inhibitor (HATi II) that strongly inhibits p300 and CBP (CREB binding protein) and weakly inhibits PCAF (p300/CBP 
associated factor) and GCN5 (homolog of yeast general control nonderepressable). Importantly, expression of MDR 1 was further increased 
in the drug resistant MCF-KCR cells, while it did not change in the parental MCF7 cells. Next, we knocked down the level of PCAF. GCN5 
and Ada2b (homolog of yeast alteration/deficiency in activation 2b) mRNA by transfecting specific siRNAs. The latter is a component of 
GCN5 containing multisubunit HAT complexes, such as hTFTC/hSTAGA. Interestingly. PCAF downregulation resulted in a reduction of 
the MDRl mRNA level in MCF7 cells but not in the MCF-KCR cells. MDRl mRNA level did not change in the drug resistant subline 
and decreased only slightly in drug sensitive cells upon GCN5 or Ada2b knockdown. These data suggest that MDRl expression can not 
be easily reduced by simple inhibition of HATs in the drug resistant cells, probably because histone acetylation is highly deregulated in 
these cells. 
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